| Autor: |
Jalili, Arsalan, Hajifathali, Abbas, Mohammadian, Mozhdeh, Sankanian, Ghazaleh, Sayahinouri, Maryam, Ghorbi, Mahmoud Dehghani, Roshandel, Elham, Aghdami, Nasser |
| Předmět: |
|
| Zdroj: |
Advanced Pharmaceutical Bulletin; Jul2023, Vol. 13 Issue 3, p469-482, 14p |
| Abstrakt: |
Hematopoietic stem cell transplantation (HSCT) is a life-saving therapy for various hematologic disorders. Due to the bone marrow suppression and its long recovery period, secondary infections, like cytomegalovirus (CMV), Epstein-Bar virus (EBV), and adenovirus (AdV), are the leading causes of morbidity and mortality in HSCT cases. Drug resistance to the antiviral pharmacotherapies makes researchers develop adoptive T cell therapies like virus-specific T cell therapy. These studies have faced major challenges such as finding the most effective T cell expansion methods, isolating the expected subtype, defining the functionality of the end-cell population, product quality control, and clinical complications after the injection. This review discusses the viral infections after HSCT, T cells characteristics during chronic viral infection, application of virus-specific T cells (VSTs) for refractory infections, standard methods for producing VSTs and their limitation, clinical experiences on VSTs, focusing on outcomes and side effects that can be helpful in decision-making for patients and further researches. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
